Differential regulation of GluA1 expression by ketamine and memantine
•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation...
Gespeichert in:
Veröffentlicht in: | Behavioural brain research 2017-01, Vol.316, p.152-159 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 159 |
---|---|
container_issue | |
container_start_page | 152 |
container_title | Behavioural brain research |
container_volume | 316 |
creator | Zhang, Ke Yamaki, Vitor Nagai Wei, Zhisheng Zheng, Yu Cai, Xiang |
description | •Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration.
Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses. |
doi_str_mv | 10.1016/j.bbr.2016.09.002 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837327573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S016643281630585X</els_id><sourcerecordid>1835370402</sourcerecordid><originalsourceid>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</originalsourceid><addsrcrecordid>eNqNkMtO5DAQRS0Egh7gA9igLNkk42ccixWChkFCmg2sLT8qyE0ejZ0g-HvcNLBErMoqn3ulOgidEFwRTOq_q8raWNH8rLCqMKY7aEEaSUspuNpFi_xRl5zR5gD9SWmFMeZYkH10QKVQqiZqgZZXoW0hwjAF0xURHufOTGEcirEtbrr5ghTwuo6Q0mZn34onmEwfBijM4IseepODAxyhvdZ0CY4_5yF6uF7eX_4r7_7f3F5e3JWOCzqVteOcNsQBrUEwZSlYqzx3jWs8EYoJxS2WHiw1LRGM-gZbqThmbcN8KyU7RGfb3nUcn2dIk-5DctB1ZoBxTpo0TLJ8nGS_QQWTWQjNKNmiLo4pRWj1OobexDdNsN6I1iudReuNaI2Vxh-Z08_62fbgvxNfZjNwvgUg-3gJEHVyAQYHPkRwk_Zj-KH-HcqBjN0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835370402</pqid></control><display><type>article</type><title>Differential regulation of GluA1 expression by ketamine and memantine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</creator><creatorcontrib>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</creatorcontrib><description>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration.
Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</description><identifier>ISSN: 0166-4328</identifier><identifier>EISSN: 1872-7549</identifier><identifier>DOI: 10.1016/j.bbr.2016.09.002</identifier><identifier>PMID: 27599619</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>AMPA receptor ; Animals ; Benzylamines - pharmacology ; Depression - drug therapy ; Disease Models, Animal ; Excitatory Amino Acid Antagonists - pharmacology ; Excitatory Postsynaptic Potentials - drug effects ; GABA Antagonists - pharmacology ; Gene Expression Regulation - drug effects ; GluA1 Ser845 ; Hippocampus - drug effects ; In Vitro Techniques ; Ketamine ; Ketamine - pharmacology ; Ketamine - therapeutic use ; Major depressive disorder ; Memantine ; Memantine - pharmacology ; Phosphinic Acids - pharmacology ; Phosphorylation - drug effects ; Picrotoxin - pharmacology ; Rats ; Rats, Sprague-Dawley ; Receptors, AMPA - metabolism ; Swimming - psychology ; Synaptic Transmission - drug effects ; Synaptosomes - drug effects ; Synaptosomes - metabolism</subject><ispartof>Behavioural brain research, 2017-01, Vol.316, p.152-159</ispartof><rights>2016 Elsevier B.V.</rights><rights>Copyright © 2016 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</citedby><cites>FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</cites><orcidid>0000-0003-0222-553X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bbr.2016.09.002$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27599619$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Ke</creatorcontrib><creatorcontrib>Yamaki, Vitor Nagai</creatorcontrib><creatorcontrib>Wei, Zhisheng</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Cai, Xiang</creatorcontrib><title>Differential regulation of GluA1 expression by ketamine and memantine</title><title>Behavioural brain research</title><addtitle>Behav Brain Res</addtitle><description>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration.
Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</description><subject>AMPA receptor</subject><subject>Animals</subject><subject>Benzylamines - pharmacology</subject><subject>Depression - drug therapy</subject><subject>Disease Models, Animal</subject><subject>Excitatory Amino Acid Antagonists - pharmacology</subject><subject>Excitatory Postsynaptic Potentials - drug effects</subject><subject>GABA Antagonists - pharmacology</subject><subject>Gene Expression Regulation - drug effects</subject><subject>GluA1 Ser845</subject><subject>Hippocampus - drug effects</subject><subject>In Vitro Techniques</subject><subject>Ketamine</subject><subject>Ketamine - pharmacology</subject><subject>Ketamine - therapeutic use</subject><subject>Major depressive disorder</subject><subject>Memantine</subject><subject>Memantine - pharmacology</subject><subject>Phosphinic Acids - pharmacology</subject><subject>Phosphorylation - drug effects</subject><subject>Picrotoxin - pharmacology</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, AMPA - metabolism</subject><subject>Swimming - psychology</subject><subject>Synaptic Transmission - drug effects</subject><subject>Synaptosomes - drug effects</subject><subject>Synaptosomes - metabolism</subject><issn>0166-4328</issn><issn>1872-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkMtO5DAQRS0Egh7gA9igLNkk42ccixWChkFCmg2sLT8qyE0ejZ0g-HvcNLBErMoqn3ulOgidEFwRTOq_q8raWNH8rLCqMKY7aEEaSUspuNpFi_xRl5zR5gD9SWmFMeZYkH10QKVQqiZqgZZXoW0hwjAF0xURHufOTGEcirEtbrr5ghTwuo6Q0mZn34onmEwfBijM4IseepODAxyhvdZ0CY4_5yF6uF7eX_4r7_7f3F5e3JWOCzqVteOcNsQBrUEwZSlYqzx3jWs8EYoJxS2WHiw1LRGM-gZbqThmbcN8KyU7RGfb3nUcn2dIk-5DctB1ZoBxTpo0TLJ8nGS_QQWTWQjNKNmiLo4pRWj1OobexDdNsN6I1iudReuNaI2Vxh-Z08_62fbgvxNfZjNwvgUg-3gJEHVyAQYHPkRwk_Zj-KH-HcqBjN0</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Zhang, Ke</creator><creator>Yamaki, Vitor Nagai</creator><creator>Wei, Zhisheng</creator><creator>Zheng, Yu</creator><creator>Cai, Xiang</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7QG</scope><scope>7TK</scope><orcidid>https://orcid.org/0000-0003-0222-553X</orcidid></search><sort><creationdate>20170101</creationdate><title>Differential regulation of GluA1 expression by ketamine and memantine</title><author>Zhang, Ke ; Yamaki, Vitor Nagai ; Wei, Zhisheng ; Zheng, Yu ; Cai, Xiang</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c452t-6c44281ce26e539b2ebb9d4c8c8d1593594b07deb2af1532d80b79403f83df773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>AMPA receptor</topic><topic>Animals</topic><topic>Benzylamines - pharmacology</topic><topic>Depression - drug therapy</topic><topic>Disease Models, Animal</topic><topic>Excitatory Amino Acid Antagonists - pharmacology</topic><topic>Excitatory Postsynaptic Potentials - drug effects</topic><topic>GABA Antagonists - pharmacology</topic><topic>Gene Expression Regulation - drug effects</topic><topic>GluA1 Ser845</topic><topic>Hippocampus - drug effects</topic><topic>In Vitro Techniques</topic><topic>Ketamine</topic><topic>Ketamine - pharmacology</topic><topic>Ketamine - therapeutic use</topic><topic>Major depressive disorder</topic><topic>Memantine</topic><topic>Memantine - pharmacology</topic><topic>Phosphinic Acids - pharmacology</topic><topic>Phosphorylation - drug effects</topic><topic>Picrotoxin - pharmacology</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, AMPA - metabolism</topic><topic>Swimming - psychology</topic><topic>Synaptic Transmission - drug effects</topic><topic>Synaptosomes - drug effects</topic><topic>Synaptosomes - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Ke</creatorcontrib><creatorcontrib>Yamaki, Vitor Nagai</creatorcontrib><creatorcontrib>Wei, Zhisheng</creatorcontrib><creatorcontrib>Zheng, Yu</creatorcontrib><creatorcontrib>Cai, Xiang</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Animal Behavior Abstracts</collection><collection>Neurosciences Abstracts</collection><jtitle>Behavioural brain research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Ke</au><au>Yamaki, Vitor Nagai</au><au>Wei, Zhisheng</au><au>Zheng, Yu</au><au>Cai, Xiang</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Differential regulation of GluA1 expression by ketamine and memantine</atitle><jtitle>Behavioural brain research</jtitle><addtitle>Behav Brain Res</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>316</volume><spage>152</spage><epage>159</epage><pages>152-159</pages><issn>0166-4328</issn><eissn>1872-7549</eissn><abstract>•Memantine potentiates Schaffer collateral-CA1 excitatory synaptic transmission in hippocampal area CA1.•Administration of memantine or ketamine enhances GluA1 S845 phosphorylation, but only ketamine elevates the expression of GluA1.•Memantine-induced potentiation of SC-CA1 synaptic phosphorylation and GluA1 phosphorylation are not occluded by GAGA receptor blockade.•Ketamine but not memantine enhances the phosphorylation of mTOR, in a time course parallel to the elevation of GluA1 expression.•Neither ketamine or memantine reduces the phosphorylation of eEF2; instead, ketamine enhances eEF2 phosphorylation 30min following administration.
Evidence from preclinical and clinical studies shows that ketamine, a noncompetitive NMDA receptor antagonist, exerts rapid and sustained antidepressant responses. However, ketamine’s psychotomimetic side effects and abuse liability limit the clinical use of the compound. Interestingly, memantine, another NMDA receptor channel blocker, processes no defined antidepressant property but is much safer and clinical tolerated. Understanding why ketamine but not memantine exhibits rapid antidepressant responses is important to elucidate the cellular signaling underlying the fast antidepressant actions of ketamine and to design a new safer generation of fast-acting antidepressants. Here we show that ketamine but memantine caused a rapid and sustained antidepressant-like responses in forced swim test (FST). Both drugs enhanced GluA1 S845 phosphorylation and potentiated Schaffer collateral-CA1 synaptic transmission. However, ketamine but not memantine elevated the expression of GluA1. Incubating acutely prepared hippocampal slices with ketamine but not memantine enhanced mTOR phosphorylation in a time course parallel to the time course of GluA1 elevation. Our results suggest that distinct properties in regulation of mTOR phosphorylation and synaptic protein expression may underlie the differential effectiveness of ketamine and memantine in their antidepressant responses.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>27599619</pmid><doi>10.1016/j.bbr.2016.09.002</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-0222-553X</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0166-4328 |
ispartof | Behavioural brain research, 2017-01, Vol.316, p.152-159 |
issn | 0166-4328 1872-7549 |
language | eng |
recordid | cdi_proquest_miscellaneous_1837327573 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | AMPA receptor Animals Benzylamines - pharmacology Depression - drug therapy Disease Models, Animal Excitatory Amino Acid Antagonists - pharmacology Excitatory Postsynaptic Potentials - drug effects GABA Antagonists - pharmacology Gene Expression Regulation - drug effects GluA1 Ser845 Hippocampus - drug effects In Vitro Techniques Ketamine Ketamine - pharmacology Ketamine - therapeutic use Major depressive disorder Memantine Memantine - pharmacology Phosphinic Acids - pharmacology Phosphorylation - drug effects Picrotoxin - pharmacology Rats Rats, Sprague-Dawley Receptors, AMPA - metabolism Swimming - psychology Synaptic Transmission - drug effects Synaptosomes - drug effects Synaptosomes - metabolism |
title | Differential regulation of GluA1 expression by ketamine and memantine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T06%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Differential%20regulation%20of%20GluA1%20expression%20by%20ketamine%20and%20memantine&rft.jtitle=Behavioural%20brain%20research&rft.au=Zhang,%20Ke&rft.date=2017-01-01&rft.volume=316&rft.spage=152&rft.epage=159&rft.pages=152-159&rft.issn=0166-4328&rft.eissn=1872-7549&rft_id=info:doi/10.1016/j.bbr.2016.09.002&rft_dat=%3Cproquest_cross%3E1835370402%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835370402&rft_id=info:pmid/27599619&rft_els_id=S016643281630585X&rfr_iscdi=true |